Amytrx Therapeutics
Amytrx Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing next-generation anti-inflammatory peptide therapies for chronic inflammatory diseases. Their lead program, AMTX-100, is a first-in-class cell-penetrating peptide that modulates inflammation by targeting importins, with potential applications across various inflammatory, autoimmune, and metabolic diseases. The company emphasizes collaboration, innovation, and advancing therapies with a focus on safety and efficacy.
Industries
Nr. of Employees
small (1-50)
Amytrx Therapeutics
Products
Clinical-stage cell-penetrating anti-inflammatory peptide (lead topical formulation)
A clinical-stage, cell-penetrating peptide therapeutic bioengineered from human protein sequences that modulates inflammation via intracellular inhibition of nuclear transport of pro-inflammatory transcription factors; developed as a topical cream with plans for multiple formulation routes.
Clinical-stage cell-penetrating anti-inflammatory peptide (lead topical formulation)
A clinical-stage, cell-penetrating peptide therapeutic bioengineered from human protein sequences that modulates inflammation via intracellular inhibition of nuclear transport of pro-inflammatory transcription factors; developed as a topical cream with plans for multiple formulation routes.
Services
Collaborative research and licensing partnerships
Establishing research collaborations, licensing agreements, and sponsored projects to apply peptide platform sequences across therapeutic indications.
Clinical trial sponsorship and management
Sponsorship and operational coordination of early-stage clinical trials, including IND-enabled studies, enrollment, and assessment of safety and exploratory biological endpoints.
CMC and formulation development management
Management of chemistry, manufacturing and control (CMC) activities and topical/multi-route formulation development via outsourced manufacturing partners.
Collaborative research and licensing partnerships
Establishing research collaborations, licensing agreements, and sponsored projects to apply peptide platform sequences across therapeutic indications.
Clinical trial sponsorship and management
Sponsorship and operational coordination of early-stage clinical trials, including IND-enabled studies, enrollment, and assessment of safety and exploratory biological endpoints.
CMC and formulation development management
Management of chemistry, manufacturing and control (CMC) activities and topical/multi-route formulation development via outsourced manufacturing partners.
Expertise Areas
- Peptide therapeutics development
- Translational immunology and immune modulation
- Formulation development (topical and multi-route)
- Preclinical safety and animal models
Key Technologies
- Cell-penetrating peptides
- Peptide bioengineering from human protein sequences
- Importin / nuclear transport modulation (NLS decoy)
- Topical cream formulation